LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Glaukos Corp

Closed

SectorHealthcare

95.45 4.13

Overview

Share price change

24h

Current

Min

91.23

Max

95.45

Key metrics

By Trading Economics

Income

15M

-18M

Sales

1.2M

107M

EPS

-0.22

Profit margin

-17.012

Employees

995

EBITDA

1.6M

-21M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+35.44% upside

Dividends

By Dow Jones

Next Earnings

30 Jul 2025

Market Stats

By TradingEconomics

Market Cap

53M

5.4B

Previous open

91.32

Previous close

95.45

News Sentiment

By Acuity

75%

25%

356 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Glaukos Corp Chart

Past performance is not a reliable indicator of future results.

Related News

15 May 2025, 22:52 UTC

Earnings
Major Market Movers

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 May 2025, 20:37 UTC

Top News
Earnings

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 May 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 May 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 May 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 May 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 May 2025, 23:14 UTC

Top News

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 May 2025, 22:46 UTC

Top News
Acquisitions, Mergers, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 May 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 May 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 May 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 May 2025, 21:58 UTC

Earnings

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 May 2025, 21:24 UTC

Earnings

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 May 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 May 2025, 20:54 UTC

Market Talk
Earnings

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 May 2025, 20:54 UTC

Earnings

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 May 2025, 20:51 UTC

Earnings

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 May 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 May 2025, 20:50 UTC

Acquisitions, Mergers, Takeovers

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 May 2025, 20:50 UTC

Earnings

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 May 2025, 20:47 UTC

Earnings

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 May 2025, 20:47 UTC

Earnings

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 May 2025, 20:47 UTC

Earnings

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 May 2025, 20:47 UTC

Earnings

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 May 2025, 20:37 UTC

Earnings

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 May 2025, 20:37 UTC

Earnings

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 May 2025, 20:37 UTC

Earnings

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 May 2025, 20:37 UTC

Earnings

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 May 2025, 20:26 UTC

Top News

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 May 2025, 20:25 UTC

Earnings

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Peer Comparison

Price change

Glaukos Corp Forecast

Price Target

By TipRanks

35.44% upside

12 Months Forecast

Average 124.09 USD  35.44%

High 165 USD

Low 86 USD

Based on 12 Wall Street analysts offering 12 month price targets forGlaukos Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

10

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

87.61 / 93Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

356 / 382 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.